Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Galunisertib · LY-2157299

Small molecule · Inhibitor of TGF-beta receptor type 1 (TGFBR1) · developed by ELI LILLY &

Phase 2 Most advanced trial
LLY Developer

What is Galunisertib?

Galunisertib is an orally available small molecule that binds the kinase domain of the TGF-beta receptor type 1 (TGFBR1), preventing activation of TGF-beta-mediated signaling. It is studied in prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY-2157299
Drug type
Small molecule
Targets
TGF-beta receptor type 1 (TGFBR1)
Mechanism
Inhibitor of TGF-beta receptor type 1 (TGFBR1)
Pathways
TGF-beta signaling pathway
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3OKH1W5LZE

Conditions studied

Prostate Cancer

More from ELI LILLY &

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Galunisertib

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.